The TLR agonist promotes DC maturation and activation, while the cell-penetrating peptide allows the antigenic domain to access the cytosolic compartment of DCs where antigen cross-presentation occurs, increasing production of antigen-specific CD8+ T cells and boosting anti-tumour immunity (93). The gene discussed is CD8A; the disease is neoplasm.